Proper integration of surgery and systemic therapy is essential for improving outcomes in renal cell carcinoma (RCC).
There is no current role for adjuvant therapy after nephrectomy for clinically localized disease. The potential benefits of neoadjuvant therapy for locally advanced nonmetastatic disease are in need of further study. In metastatic disease, the proper integration of cytoreductive surgery and systemic therapy remains to be elucidated. Presurgical targeted therapy is feasible and may be beneficial. Pending the results of randomized controlled trials, upfront cytoreductive nephrectomy in appropriate patients will likely continue as the paradigm of choice in metastatic RCC.
Written by:
Kenney PA, Wood CG. Are you the author?
Urologic Oncology, Department of Urology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1373, Houston, TX 77030, USA.
Reference: Urol Clin North Am. 2012 May;39(2):211-31, vii.
doi: 10.1016/j.ucl.2012.01.005
PubMed Abstract
PMID: 22487764
UroToday.com Renal Cancer Section